SCHEMBL8523665

SCHEMBL8523665

Cc1cccc2c1CCCC(=O)N2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.55
CREBBP Q92793 4/20 0.45
NPC1 O15118 1/20 0.44
MAPK13 O15264 1/20 0.44
MAPK12 P53778 1/20 0.44
MAPK11 Q15759 1/20 0.44
MAPK14 Q16539 1/20 0.44
BRD4 O60885 2/20 0.44
HTR5A P47898 1/20 0.44
CRBN Q96SW2 4/20 0.43
PARP1 P09874 1/20 0.42
PARP10 Q53GL7 1/20 0.42
PARP11 Q9NR21 1/20 0.42
CCNB2 O95067 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
GSK3B P49841 1/20 0.41
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1764170 0.91 NPC1 (0.50) MAPTCREBBPNPC1MAPK13MAPK12
SCHEMBL29754448 0.91 NPC1 (0.50) MAPTCREBBPNPC1MAPK13MAPK12
SCHEMBL152281 0.81 CCNB2 (0.54) MAPTCREBBPBRD4HTR5ACCNB2
SCHEMBL29622074 0.81 CCNB2 (0.54) MAPTCREBBPBRD4HTR5ACCNB2
SCHEMBL6407953 0.80 MAPT (0.53) MAPTCREBBPNPC1MAPK13MAPK12
SCHEMBL2408663 0.80 MAPT (0.53) MAPTCREBBPNPC1MAPK13MAPK12
SCHEMBL427457 0.80 MAPT (0.53) MAPTNPC1MAPK13MAPK12MAPK11
SCHEMBL20777511 0.80 HTR5A (0.52) CREBBPBRD4HTR5APARP1PARP10
SCHEMBL885653 0.80 MAPT (0.49) MAPTCREBBPNPC1MAPK13MAPK12
SCHEMBL16132462 0.78 MAPT (0.46) MAPTNPC1MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022109179-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2022-05-27 WO disclosed
US-20190142852-A1 HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-05-16 US disclosed
WO-1999015524-A1 THIAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190142852-A1 HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE HCRTR1, NPSR1, NTSR1 MAPT 4334/4885CREBBP 3500/4885NPC1 1606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.